If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Vincenzo Di Lauro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

letrozole Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Lymph Nodes Medicine & Life Sciences
Quality of Life Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Appointments and Schedules Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Random Allocation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2017 2020

Open Access
letrozole
Lymph Nodes
Quality of Life
Clinical Trials
Breast Neoplasms

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

on behalf of the SOLE Investigators, May 14 2019, In : British Journal of Cancer. 120, 10, p. 959-967 9 p.

Research output: Contribution to journalArticle

letrozole
Lymph Nodes
Quality of Life
Breast Neoplasms
Appointments and Schedules

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

on behalf of the SOLE Investigators, May 14 2019, In : British Journal of Cancer. 120, 10, p. 959-967 9 p.

Research output: Contribution to journalArticle

letrozole
Lymph Nodes
Quality of Life
Breast Neoplasms
Appointments and Schedules

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

on behalf of the SOLE Investigators, Jan 1 2018, In : The Lancet Oncology. 19, 1, p. 127-138 12 p.

Research output: Contribution to journalArticle

letrozole
Breast Neoplasms
Disease-Free Survival
Therapeutics

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Colleoni, M., Luo, W., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G., Neven, P., Hitre, E., Graas, M. P., Simoncini, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., Di Lauro, V., Gombos, A. & 31 others, Ruhstaller, T., Burstein, H., Ribi, K., Bernhard, J., Viale, G., Maibach, R., Rabaglio-Poretti, M., Gelber, R. D., Coates, A. S., Di Leo, A., Regan, M. M., Goldhirsch, A., Vandebroek, A., Berliere, M., Mitine, C., Vuylsteke, P., Borms, M., D'Hondt, R., Glorieux, P., Mebis, J., Verhoeven, D., Coibion, M., Forget, F., Duck, L., Verhoeven, D., Wyendaele, W., Barbeaux, A., Salmon, J. P., Bernardo, A., Amadori, D. & on behalf of the SOLE Investigators, Jan 1 2018, In : The Lancet Oncology. 19, 1, p. 127-138 12 p.

Research output: Contribution to journalArticle

letrozole
Breast Neoplasms
Disease-Free Survival
Therapeutics